Upstream Bio’s UPB-101 addresses allergic and inflammatory diseases, including asthma. Credit: natatravel via Shutterstock.com.

Clinical-stage biotech company Upstream Bio has raised $200m in a Series B financing round to advance its UPB-101 to treat allergic and inflammatory diseases.

Co-led by Venrock Healthcare Capital Partners (Venrock) and Enavate Sciences, the financing round has seen participation from new investors Wellington Management and Bain Capital Life Sciences.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Series A investors Omega Funds, Altshuler Shaham Provident Funds, Access Biotechnology, Samsara BioCapital, TCG X, OrbiMed, Decheng Capital and HBM Healthcare Investments have also participated in the financing round.

Upstream Bio will use the funds to advance its UPB-101 into Phase II trials to treat asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

It is also preparing for a swift transition to Phase III development.

A new recombinant fully human immunoglobulin G1 monoclonal antibody, UPB-101, is now being evaluated in a Phase 1b trial to treat asthma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It targets the human thymic stromal lymphopoietin receptor to inhibit signalling.

The therapy showed that it can inhibit the production of cytokine from both CD4+ T cells and ILC2, and completely suppressed skin allergic reactions in a monkey model in pre-clinical trials.

Upstream Bio CEO Samantha Truex stated: “Our IND has been cleared by the FDA to pursue Phase II programmes in both asthma and CRSwNP.

“These studies are designed to generate evidence that targeting TSLPR may offer people suffering from asthma and CRSwNP a safe and effective therapy with the advantage of less frequent dosing.”

The company also announced that Enavate Sciences Commercialisation executive vice-president Dr Edd Fleming and Venrock partner Alex Rosen have joined its board of directors.